#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypochromic anaemia Nephrotic syndrome Malignant neoplasm of choroid Uveal melanoma Liposarcoma metastatic Osteochondrodysplasia Neuroendocrine carcinoma metastatic Heavy menstrual bleeding Methylmalonic acidaemia Primary hyperoxaluria Skin cancer Transitional cell carcinoma General anaesthesia Marginal zone lymphoma Polycystic liver disease More trials…

    Learn about Rare Diseases

    Optic glioma Gastrointestinal stromal tumour – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Hereditary ataxia – Basic Information Amyotrophic lateral sclerosis KBG syndrome – Basic Information Factor IX deficiency – Basic Information Bronchiolitis obliterans syndrome – Diagnostics X-linked lymphoproliferative syndrome – Basic Information Chordoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [14C] DC-806 Rgx-202 Olopatadine Hydrochloride Tolcapone IDROXIOLEIC ACID SAR445399 Mva-209-Fsp-B3 Etifoxine Hydrochloride Dermatophagoides Farinae Edg-5506 LIPASE ZOREVUNERSEN SODIUM Quercus Robur Pollen Extract Lidocaine Dexamethasone Tucidinostat Prasugrel Hydrobromide Ht-29-A Temocillin Sodium Eptacog Alfa (Activated) More therapies…

    Learn about Your Condition

    Gastric cancer recurrent Burning mouth syndrome Fallopian tube cancer stage IV Psychological trauma Uterine leiomyosarcoma Diabetic foot infection Colorectal cancer stage III Cryoglobulinaemia Dystonic tremor Haemoglobinuria Cancer fatigue Anal abscess Cluster headache Binge eating Large cell lung cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Multiprofile Hospital For Active Treatment…

University Multiprofile Hospital For Active Treatment Sofiamed OOD

Bulevard D-R G.m.dimitrov 16, Sofia, 1797, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • Long-Term Study of Imeroprubart in Adults With Graves’ Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Graves’ disease
    Investigated Drugs:
    • IMEROPRUBART
    Belgium Bulgaria Czechia Germany Greece Hungary +5

  • Study of GS-4321 for Healthy People and Patients With Chronic Hepatitis Delta Virus Infection

    Recruiting

    2 1
    Investigated Diseases:
    • Hepatitis D
    Investigated Drugs:
    • GS-4321
    Bulgaria Germany Italy Romania

  • A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

    Recruiting

    3 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Bulgaria Croatia Czechia France Germany Greece +6

  • A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

    Recruiting

    3 1
    Bulgaria Croatia Czechia France Germany Greece +6

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Trastuzumab Deruxtecan
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azacitidine
    • Lisaftoclax
    Belgium Bulgaria Czechia Finland France Germany +7

  • Study on the Effectiveness and Safety of Efgartigimod IV for Adults with Primary Immune Thrombocytopenia

    Recruiting

    3 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Bulgaria Croatia Czechia France Germany +8

  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Bulgaria Czechia Denmark Finland France Germany +8

  • Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    Bulgaria Hungary Poland Romania
1 2 3 … 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!